RFK Jr. forces FDA to reconsider 12 unproven peptides after 2023 ban Ars Technica Public Meeting: FDA Rare Disease Day 2026 02 23 2026 FDA EllieMD Dihexa A federal review is underway that could reclassify 14 peptides into FDA Category 1. This change that may influence how peptide therapies are accessed in the U.S. Here's what experts are FDA's Overreach on Compounded Peptides Q1 2026 Recap: Top FDA Approvals HCPLive